FR2413974A1
(fr)
|
1978-01-06 |
1979-08-03 |
David Bernard |
Sechoir pour feuilles imprimees par serigraphie
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
US4754065A
(en)
|
1984-12-18 |
1988-06-28 |
Cetus Corporation |
Precursor to nucleic acid probe
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US4777127A
(en)
|
1985-09-30 |
1988-10-11 |
Labsystems Oy |
Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
GB8611832D0
(en)
|
1986-05-15 |
1986-06-25 |
Holland I B |
Polypeptide
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
GB8702816D0
(en)
|
1987-02-07 |
1987-03-11 |
Al Sumidaie A M K |
Obtaining retrovirus-containing fraction
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
US4975278A
(en)
|
1988-02-26 |
1990-12-04 |
Bristol-Myers Company |
Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
|
US5422120A
(en)
|
1988-05-30 |
1995-06-06 |
Depotech Corporation |
Heterovesicular liposomes
|
AP129A
(en)
|
1988-06-03 |
1991-04-17 |
Smithkline Biologicals S A |
Expression of retrovirus gag protein eukaryotic cells
|
US5037743A
(en)
|
1988-08-05 |
1991-08-06 |
Zymogenetics, Inc. |
BAR1 secretion signal
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
US5047335A
(en)
|
1988-12-21 |
1991-09-10 |
The Regents Of The University Of Calif. |
Process for controlling intracellular glycosylation of proteins
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
JP2752788B2
(ja)
|
1989-01-23 |
1998-05-18 |
カイロン コーポレイション |
感染および過剰増殖障害の為の組換え療法
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
US6673776B1
(en)
|
1989-03-21 |
2004-01-06 |
Vical Incorporated |
Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
|
DE69034168T3
(de)
|
1989-03-21 |
2013-04-11 |
Vical, Inc. |
Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
|
DE69029036T2
(de)
|
1989-06-29 |
1997-05-22 |
Medarex Inc |
Bispezifische reagenzien für die aids-therapie
|
WO1991002805A2
(en)
|
1989-08-18 |
1991-03-07 |
Viagene, Inc. |
Recombinant retroviruses delivering vector constructs to target cells
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
ZA911974B
(en)
|
1990-03-21 |
1994-08-22 |
Res Dev Foundation |
Heterovesicular liposomes
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
KR100272077B1
(ko)
|
1990-08-29 |
2000-11-15 |
젠팜인터내셔날,인코포레이티드 |
이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
ATE164395T1
(de)
|
1990-12-03 |
1998-04-15 |
Genentech Inc |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
US5278299A
(en)
|
1991-03-18 |
1994-01-11 |
Scripps Clinic And Research Foundation |
Method and composition for synthesizing sialylated glycosyl compounds
|
JPH06507398A
(ja)
|
1991-05-14 |
1994-08-25 |
リプリジェン コーポレーション |
Hiv感染治療のための異種複合抗体
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
EP0940468A1
(en)
|
1991-06-14 |
1999-09-08 |
Genentech, Inc. |
Humanized antibody variable domain
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
GB9115364D0
(en)
|
1991-07-16 |
1991-08-28 |
Wellcome Found |
Antibody
|
DK0648271T3
(da)
|
1991-08-20 |
2003-07-21 |
Us Gov Health & Human Serv |
Adenovirusmedieret overførsel af gener til mave-/tarmkanal
|
AU669124B2
(en)
|
1991-09-18 |
1996-05-30 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing humanized chimera antibody
|
DE69229477T2
(de)
|
1991-09-23 |
1999-12-09 |
Cambridge Antibody Tech |
Methoden zur Herstellung humanisierter Antikörper
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
WO1993010218A1
(en)
|
1991-11-14 |
1993-05-27 |
The United States Government As Represented By The Secretary Of The Department Of Health And Human Services |
Vectors including foreign genes and negative selective markers
|
AU3144193A
(en)
|
1991-11-21 |
1993-06-15 |
Board Of Trustees Of The Leland Stanford Junior University |
Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
|
GB9125623D0
(en)
|
1991-12-02 |
1992-01-29 |
Dynal As |
Cell modification
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
EP0650370A4
(en)
|
1992-06-08 |
1995-11-22 |
Univ California |
METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
|
WO1993025698A1
(en)
|
1992-06-10 |
1993-12-23 |
The United States Government As Represented By The |
Vector particles resistant to inactivation by human serum
|
GB2269175A
(en)
|
1992-07-31 |
1994-02-02 |
Imperial College |
Retroviral vectors
|
JPH08500017A
(ja)
|
1992-08-17 |
1996-01-09 |
ジェネンテク,インコーポレイテッド |
二特異的免疫アドヘジン
|
US6210671B1
(en)
|
1992-12-01 |
2001-04-03 |
Protein Design Labs, Inc. |
Humanized antibodies reactive with L-selectin
|
CA2145641C
(en)
|
1992-12-03 |
2008-05-27 |
Richard J. Gregory |
Pseudo-adenovirus vectors
|
ES2188612T3
(es)
|
1993-04-22 |
2003-07-01 |
Skyepharma Inc |
Liposomas multivesiculares de ciclodextrina para encapsular compuestos farmacologicos y metodos para su uso.
|
US6180377B1
(en)
|
1993-06-16 |
2001-01-30 |
Celltech Therapeutics Limited |
Humanized antibodies
|
DE69434486T2
(de)
|
1993-06-24 |
2006-07-06 |
Advec Inc. |
Adenovirus vektoren für gentherapie
|
CA2158937C
(en)
|
1993-09-15 |
2006-01-03 |
Thomas W. Dubensky, Jr. |
Recombinant alphavirus vectors
|
US6015686A
(en)
|
1993-09-15 |
2000-01-18 |
Chiron Viagene, Inc. |
Eukaryotic layered vector initiation systems
|
ATE437232T1
(de)
|
1993-10-25 |
2009-08-15 |
Canji Inc |
Rekombinanter adenoviren-vektor und verfahren zur verwendung
|
CN1099868C
(zh)
|
1993-11-16 |
2003-01-29 |
斯卡法玛公司 |
具有控制释放活性成分作用的囊
|
US6436908B1
(en)
|
1995-05-30 |
2002-08-20 |
Duke University |
Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
|
CA2158977A1
(en)
|
1994-05-09 |
1995-11-10 |
James G. Respess |
Retroviral vectors having a reduced recombination rate
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
WO1996017072A2
(en)
|
1994-11-30 |
1996-06-06 |
Chiron Viagene, Inc. |
Recombinant alphavirus vectors
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
DE69739286D1
(de)
|
1996-05-06 |
2009-04-16 |
Oxford Biomedica Ltd |
Rekombinationsunfähige retrovirale vektoren
|
US6376471B1
(en)
|
1997-10-10 |
2002-04-23 |
Johns Hopkins University |
Gene delivery compositions and methods
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6849425B1
(en)
|
1999-10-14 |
2005-02-01 |
Ixsys, Inc. |
Methods of optimizing antibody variable region binding affinity
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
ATE373078T1
(de)
|
2000-02-24 |
2007-09-15 |
Xcyte Therapies Inc |
Gleichzeitige stimulation und konzentration von zellen
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
AU2001247616B2
(en)
|
2000-04-11 |
2007-06-14 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
PT1575517E
(pt)
|
2002-12-24 |
2012-05-28 |
Rinat Neuroscience Corp |
Anticorpos anti-ngf e métodos de utilização dos mesmos
|
JP5356648B2
(ja)
|
2003-02-20 |
2013-12-04 |
シアトル ジェネティックス, インコーポレイテッド |
抗cd70抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
|
WO2006113909A2
(en)
*
|
2005-04-19 |
2006-10-26 |
Seattle Genetics, Inc. |
Humanized anti-cd70 binding agents and uses thereof
|
US20080025989A1
(en)
*
|
2003-02-20 |
2008-01-31 |
Seattle Genetics, Inc. |
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
US20120294863A1
(en)
|
2004-10-15 |
2012-11-22 |
Seattle Genetics, Inc. |
Anti-CD70 Antibody and Its Use for the Treatment and Prevention of Cancer and Immune Disorders
|
WO2006044643A2
(en)
|
2004-10-15 |
2006-04-27 |
Seattle Genetics, Inc. |
Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
US7641903B2
(en)
|
2004-10-15 |
2010-01-05 |
Seattle Genetics, Inc. |
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
US8337838B2
(en)
|
2004-10-15 |
2012-12-25 |
Seattle Genetics, Inc. |
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
US7314622B2
(en)
|
2005-04-15 |
2008-01-01 |
Neogenix Oncology, Inc. |
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
PE20071101A1
(es)
|
2005-08-31 |
2007-12-21 |
Amgen Inc |
Polipeptidos y anticuerpos
|
JP2009509510A
(ja)
|
2005-09-26 |
2009-03-12 |
メダレックス インコーポレーティッド |
Cd70に対するヒトモノクローナル抗体
|
JP2010513306A
(ja)
|
2006-12-14 |
2010-04-30 |
メダレックス インコーポレーティッド |
Cd70に結合するヒト抗体およびその使用
|
EP2335744A4
(en)
|
2008-08-26 |
2011-07-27 |
Univ Hokkaido Nat Univ Corp |
BONE-FILLING AGENT FOR INTRODUCING CARTILAGE REGENERATION
|
CA2797981C
(en)
|
2010-05-14 |
2019-04-23 |
Rinat Neuroscience Corporation |
Heterodimeric proteins and methods for producing and purifying them
|
JP2013544082A
(ja)
|
2010-10-27 |
2013-12-12 |
セレクティス |
二本鎖破断−誘導変異誘発の効率を増大させる方法
|
NZ706016A
(en)
|
2010-10-27 |
2016-10-28 |
Baylor College Medicine |
Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
|
EP2635310A2
(en)
|
2010-11-05 |
2013-09-11 |
Rinat Neuroscience Corp. |
Engineered polypeptide conjugates and methods for making thereof using transglutaminase
|
US9765148B2
(en)
|
2011-03-16 |
2017-09-19 |
Argen-X N.V. |
Antibodies to CD70
|
CA2849318C
(en)
|
2011-09-22 |
2019-11-12 |
Amgen Inc. |
Cd27l antigen binding proteins
|
GB201206559D0
(en)
|
2012-04-13 |
2012-05-30 |
Ucl Business Plc |
Polypeptide
|
US20150017136A1
(en)
|
2013-07-15 |
2015-01-15 |
Cellectis |
Methods for engineering allogeneic and highly active t cell for immunotherapy
|
PT2893004T
(pt)
|
2012-09-04 |
2019-01-21 |
Cellectis |
Recetor de antígeno quimérico de cadeia múltipla e utilizações do mesmo
|
RU2725542C2
(ru)
|
2013-05-13 |
2020-07-02 |
Селлектис |
Способы конструирования высокоактивных т-клеток для иммунотерапии
|
CN105431532B
(zh)
|
2013-05-13 |
2021-04-06 |
瑟勒提斯公司 |
Cd19特异性嵌合抗原受体及其用途
|
EP3309248B1
(en)
|
2013-05-29 |
2021-06-09 |
Cellectis |
Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
|
JP6521959B2
(ja)
|
2013-07-31 |
2019-05-29 |
ライナット ニューロサイエンス コーポレイション |
操作されたポリペプチドコンジュゲート
|
JP2016531920A
(ja)
|
2013-09-05 |
2016-10-13 |
アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップAduro Biotech Holdings, Europe B.V. |
Cd70結合ペプチドおよびそれに関連する方法、プロセスおよび用途
|
CN104442012A
(zh)
|
2013-10-23 |
2015-03-25 |
冯林 |
一种文件修改喷墨装置
|
PL3105317T3
(pl)
|
2014-02-14 |
2019-02-28 |
Cellectis |
Komórki do immunoterapii zaprojektowane do celowania antygenu obecnego zarówno na komórkach odpornościowych, jak i komórkach patologicznych
|
TW201609812A
(zh)
*
|
2014-07-31 |
2016-03-16 |
安美基研究(慕尼黑)公司 |
最佳化之跨物種特異性雙特異性單鏈抗體構築體
|
BR112017014547A2
(pt)
|
2015-01-26 |
2018-01-16 |
Cellectis |
sistemas de receptor de antígeno quimérico dirigidos por mab para classificação/depleção de células imunes engenheiradas
|
DE102015101304B3
(de)
|
2015-01-29 |
2016-03-17 |
Fujitsu Technology Solutions Intellectual Property Gmbh |
Rackserver für ein Serverrack
|
AU2016248946B2
(en)
|
2015-04-13 |
2022-03-10 |
Pfizer Inc. |
Therapeutic antibodies and their uses
|
BR112017019914A2
(pt)
|
2015-04-13 |
2018-06-19 |
Pfizer |
receptores de antígenos quiméricos direcionados para antígeno de amadurecimento de células b
|
TWI717375B
(zh)
*
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
WO2017125831A1
(en)
|
2016-01-21 |
2017-07-27 |
Pfizer Inc. |
Mono and bispecific antibodies for epidermal growth factor receptor variant iii and cd3 and their uses
|
EA039859B1
(ru)
*
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
AR110979A1
(es)
|
2017-02-14 |
2019-05-22 |
Kite Pharma Inc |
Moléculas de unión a cd70 y métodos de uso de las mismas
|
CN112020518A
(zh)
|
2018-02-01 |
2020-12-01 |
辉瑞公司 |
靶向cd70的嵌合抗原受体
|